Experimental Hematology and Oncology,
Год журнала:
2023,
Номер
12(1)
Опубликована: Июль 27, 2023
Abstract
The
outbreak
of
coronavirus
disease
2019
(COVID-19)
posed
an
unprecedented
challenge
on
public
health
systems.
Despite
the
measures
put
in
place
to
contain
it,
COVID-19
is
likely
continue
experiencing
sporadic
outbreaks
for
some
time,
and
individuals
will
remain
susceptible
recurrent
infections.
Chimeric
antigen
receptor
(CAR)-T
recipients
are
characterized
by
durable
B-cell
aplasia,
hypogammaglobulinemia
loss
T-cell
diversity,
which
lead
increased
proportion
severe/critical
cases
a
high
mortality
rate
after
infection.
Thus,
treatment
decisions
have
become
much
more
complex
require
greater
caution
when
considering
CAR
immunotherapy.
Hence,
we
reviewed
current
understanding
reported
clinical
experience
management
CAR-T
therapy.
After
panel
discussion,
proposed
rational
procedure
pertaining
with
aim
maximizing
benefit
therapy
post
pandemic
era.
Vaccines,
Год журнала:
2023,
Номер
11(1), С. 107 - 107
Опубликована: Янв. 1, 2023
COVID-19
virus,
since
the
detection
of
first
case
in
Wuhan
2019,
has
caused
a
worldwide
pandemic
with
significant
human,
economic
and
social
costs.
Fortunately,
several
vaccines
treatments,
both
IV
oral,
are
currently
approved
against
virus.
Paxlovid
is
an
oral
treatment
option
for
patients
mild-to-moderate
disease,
it
effectively
reduces
disease
severity
high-risk
patients.
antiviral
that
consists
combination
nirmatrelvir
ritonavi.
As
medication
suitable
outpatient
treatment,
cost,
hospitalization
mortality
associated
infection.
The
pregnant
population
category
disease.
Given
their
exclusion
clinical
trials,
there
limited
data
regarding
use
lactating
women.
Indirect
evidence
from
ritonavir
as
part
HAART
therapy
HIV
shown
no
teratogenicity.
Moreover,
animal
studies
on
do
not
suggest
This
article
summarizes
available
during
pregnancy
ongoing
trials.
We
also
review
recommendations
major
societies
breastfeeding
Reviews in Medical Virology,
Год журнала:
2023,
Номер
33(5)
Опубликована: Июль 23, 2023
Abstract
Our
study
is
aimed
to
access
the
efficacy
and
safety
outcomes
for
coronavirus
disease
2019
(COVID‐19)
patients
treated
with
Paxlovid.
According
inclusion
exclusion
criteria,
databases
were
used
retrieve
articles
from
1
January
2020
2023.
Article
screening,
quality
evaluation
data
extraction
completed
cross‐checked.
The
meta‐analysis
trial
sequential
analysis
(TSA)
conducted
using
RevMan,
StataMP,
TSA
software.
A
total
of
42
original
included.
Overall
results
showed
that
death,
hospitalisation,
death
or
emergency
department
(ED)
visit,
intensive
care
unit
(ICU)
admission,
extra
oxygen
requirement
outcomes,
every
odds
ratio
(OR)
was
<1
p
<
0.05.
For
rebound
outcome,
OR
>1
>
adverse
events
(AEs)
In
conclusion,
Paxlovid
effectively
reduced
risks
ED
ICU
requirement.
There
no
significant
statistical
difference
considering
rebound,
but
people
should
pay
attention
possible
AEs.
However,
AEs
observations
in
certain
subgroups
suggested
conclusions
contrary
overall
meta‐analysis.
Trial
indicated
these
two
have
a
risk
false
negative
positive
conclusions,
so
additional
studies
are
needed
further
validation.
medRxiv (Cold Spring Harbor Laboratory),
Год журнала:
2023,
Номер
unknown
Опубликована: Янв. 23, 2023
ABSTRACT
Current
guidelines
prioritize
the
use
of
Azvudine
in
coronavirus
disease
2019
(COVID-19)
patients.
However,
clinical
effectiveness
real-world
studies
was
lacking,
despite
trials
showed
shorter
time
nucleic
acid
negative
conversion.
To
evaluate
following
treatment
hospitalized
COVID-19
patients,
we
identified
1505
patients
during
study
period,
with
a
follow-up
up
to
29
days.
After
exclusions
and
propensity
score
matching,
included
226
recipients
matched
controls.
The
lower
crude
incidence
rate
composite
progression
outcome
(4.21
vs.
10.39
per
1000
person-days,
P
=0.041)
all-cause
mortality
(1.57
6.00
=0.027)
were
observed
among
compared
rates
initiation
invasive
mechanical
ventilation
also
statistically
different
between
groups
according
log-rank
tests
(
=0.020).
associated
significantly
risks
(hazard
ratio
[HR]:
0.43;
95%
confidence
interval
[CI]:
0.18
0.99)
death
(HR:
0.26;
CI:
0.07
0.94)
Subgroup
analyses
indicated
robustness
point
estimates
HRs
(ranged
from
0.14
0.84).
Notably,
male
had
stronger
than
female
respect
both
death.
These
findings
suggest
that
substantial
benefits
should
be
considered
for
this
population
Viruses,
Год журнала:
2024,
Номер
16(1), С. 112 - 112
Опубликована: Янв. 12, 2024
This
study
investigates
the
intricate
interplay
between
Metabolic-associated
Fatty
Liver
Disease
(MAFLD)
and
COVID-19,
exploring
impact
of
MAFLD
on
disease
severity,
outcomes,
efficacy
antiviral
agent
Paxlovid
(nirmatrelvir/ritonavir).
MAFLD,
affecting
a
quarter
global
population,
emerges
as
potential
risk
factor
for
severe
yet
underlying
pathophysiological
mechanisms
remain
elusive.
focuses
clinical
significance
Paxlovid,
first
orally
bioavailable
granted
Emergency
Use
Authorization
in
United
States.
Notably,
outcomes
from
phase
II/III
trials
exhibit
an
88%
relative
reduction
COVID-19-associated
hospitalization
or
mortality
among
high-risk
patients.
Despite
conflicting
data
association
COVID-19
this
research
strives
to
bridge
gap
by
evaluating
effectiveness
patients
with
addressing
scarcity
relevant
studies.
Expert Opinion on Drug Safety,
Год журнала:
2025,
Номер
unknown, С. 1 - 8
Опубликована: Фев. 27, 2025
Nirmatrelvir/ritonavir,
commonly
known
as
Paxlovid,
is
one
of
the
main
drugs
used
to
treat
COVID-19.
Neurological
disorders
are
among
adverse
drug
reactions
(ADRs)
linked
yet
comprehensive
data-mining
studies
based
on
real-world
neurological
events
induced
by
Paxlovid
lacking.
It
an
observational
study,
reduce
risk
bias
affected
COVID-19
disease,
our
study
included
only
patients
with
disease.
In
this
case,
disproportionate
analysis
performed
using
Report
Odds
Ratio
(ROR)
and
its
95%
Confidence
Interval
(CI).
We
screened
compared
all
medications
associated
(N
=
439)
found
that
22
these
were
reactions.
was
a
threefold
greater
number
other
combined
11,792),
strong
signal
value
(ROR
2.27).
Compared
COVID-19-related
drugs,
has
highest
stronger
for
neurologic-related
Clinicians
should
pay
special
attention
female
taking
within
first
30
days,
monitoring
symptoms
such
dysgeusia,
ageusia,
headache,
anosmia.
addition,
headache
anosmia
not
uncommon
occurrences
mentioned
in
instructions
be
noted.
Viruses,
Год журнала:
2023,
Номер
15(4), С. 976 - 976
Опубликована: Апрель 16, 2023
Vaccination
against
SARS-CoV-2
and
the
prevalence
of
Omicron
variants
have
reduced
risk
severe
clinical
progress
COVID-19.
However,
breakthrough
infections
has
increased,
early
administration
an
effective
antiviral
treatment
is
significant
in
order
to
prevent
progression
COVID-19
vulnerable
patients
with
comorbidities.Adults
confirmed
infection
were
included
a
matched-pair
retrospective
study
based
on
age,
gender,
comorbidities
vaccination
status.
They
divided
into
two
groups:
group
A
(n
=
200)
consisted
outpatients
at
increased
who
treated
nirmatrelvir/ritonavir
B
non-hospitalized
did
not
receive
treatment.
Demographic
data,
outcome
(death,
intubation),
days
hospitalization,
time
for
recovery,
adverse
events
compliance
reported.The
median
age
(75.24
±
13.12
years
76.91
14.02
comparison
group)
proportion
males
(59%
vs.
60.5%,
respectively)
similar
between
groups.
total
6.5%
10.5%
unvaccinated
SARS-CoV-2.
Three
from
(1.5%)
one
hundred
eleven
(55.5%)
required
hospitalization.
The
duration
hospitalization
(3
10
B,
p
<
0.001)
needed
recovery
(5
9
days,
was
shorter
group.
rebound
within
8-12
after
diagnosis
documented
8%
B.Oral
high-risk
safe
preventing
pneumonia.
Early
agents
combined
full
scheme
avoid
outcomes.
The Lancet Healthy Longevity,
Год журнала:
2023,
Номер
4(8), С. e409 - e420
Опубликована: Июль 14, 2023
Older
adults
(aged
≥60
years)
were
prioritised
for
COVID-19
booster
vaccination
due
to
severe
outcome
risk,
but
the
risk
this
group
is
also
affected
by
previous
SARS-CoV-2
infection
and
vaccination.
We
estimated
vaccine
effectiveness
against
omicron-associated
hospitalisation
in
older
previously
documented
infection,
time
since
last
immunological
event,
age
group.This
was
a
population-based
test-negative
case-control
study
done
Quebec,
Canada,
during
BA.1
dominant
(December,
2021,
March,
2022),
BA.2
(April
June,
BA.4/5
(July
November,
2022)
periods
using
provincial
laboratory,
immunisation,
hospitalisation,
chronic
disease
surveillance
databases.
included
with
symptoms
associated
who
tested
acute-care
hospitals.
Cases
defined
as
patients
hospitalised
within
14
days
after
testing
positive;
controls
negative.
Analyses
spanned
3-14
months
dose
or
infection.
Logistic
regression
models
compared
mRNA
versus
unvaccinated
infection-naive
participants.Between
Dec
26,
Nov
5,
2022,
we
174
819
specimens
(82
870
[47·4%]
from
men
91
949
[52·6%]
women;
8455
cases
166
364
controls),
taken
2951
48
724
period;
1897
41
702
3607
75
938
period.
In
participants
naive,
improved
number,
consistent
shorter
median
dose,
decreased
more
recent
omicron
subvariants.
Four-dose
96%
(95%
CI
93-98)
period,
84%
(81-87)
68%
(63-72)
Regardless
of
number
(two
five
doses)
timing
hybrid
protection
than
90%,
persisted
at
least
6-8
months,
did
not
decline
age.Older
both
two
doses
appear
be
well
protected
prolonged
period
subvariants,
including
BA.4/5.
Ensuring
that
are
naive
remain
up
date
might
reduce
hospitalisations
most
efficiently.Ministère
de
la
Santé
et
des
Services
Sociaux
du
Québec.For
French
translation
abstract
see
Supplementary
Materials
section.
International Journal of Molecular Sciences,
Год журнала:
2023,
Номер
24(11), С. 9353 - 9353
Опубликована: Май 27, 2023
Type
I
and
III
Interferons
(IFNs)
are
the
first
lines
of
defense
in
microbial
infections.
They
critically
block
early
animal
virus
infection,
replication,
spread,
tropism
to
promote
adaptive
immune
response.
IFNs
induce
a
systemic
response
that
impacts
nearly
every
cell
host,
while
type
IFNs’
susceptibility
is
restricted
anatomic
barriers
selected
cells.
Both
IFN
types
critical
cytokines
for
antiviral
against
epithelium-tropic
viruses
being
effectors
innate
immunity
regulators
development
Indeed,
essential
limit
replication
at
stages
thus
reducing
viral
spread
pathogenesis.
However,
many
have
evolved
strategies
evade
The
Coronaviridae
with
largest
genome
among
RNA
viruses.
Severe
Acute
Respiratory
Syndrome-Coronavirus-2
(SARS-CoV-2)
caused
coronavirus
disease
2019
(COVID-19)
pandemic.
has
numerous
contrast
system
immunity.
We
intend
describe
virus-mediated
evasion
responses
by
going
through
main
phases:
First,
molecular
mechanisms
involved;
second,
role
genetic
background
production
during
SARS-CoV-2
infection;
third,
potential
novel
approaches
pathogenesis
restoring
endogenous
sensitivity
sites
infection.